These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16027401)

  • 1. A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjects.
    Karyekar CS; Pradhan RS; Freeney T; Ji Q; Edeki T; Chiu W; Awni WM; Locke C; Schwartz LB; Granneman RG; O'Dea R
    J Clin Pharmacol; 2005 Aug; 45(8):910-8. PubMed ID: 16027401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.
    Tejani A; Alexander S; Ettenger R; Lerner G; Zimmerman J; Kohaut E; Briscoe DM
    Pediatr Transplant; 2004 Apr; 8(2):151-60. PubMed ID: 15049795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
    Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
    J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers.
    Wong SL; Drajesk J; Chang M; Lanni C; Witt G; Hansen R; Awni WM
    Clin Pharmacol Ther; 1998 Mar; 63(3):324-31. PubMed ID: 9542476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions.
    Vetrovec GW; Rizik D; Williard C; Snead D; Piotrovski V; Kopia G
    Catheter Cardiovasc Interv; 2006 Jan; 67(1):32-7. PubMed ID: 16342216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers.
    Othman AA; Lenz RA; Zhang J; Li J; Awni WM; Dutta S
    J Clin Pharmacol; 2011 Apr; 51(4):512-26. PubMed ID: 20495134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals.
    Steudel W; Dingmann C; Zhang YL; Bendrick-Peart J; Clavijo C; Shulze J; Betts R; Christians U
    J Clin Pharmacol; 2011 Jan; 51(1):29-39. PubMed ID: 20305057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
    Lasseter KC; Shaughnessy L; Cummings D; Pezzullo JC; Wargin W; Gagnon R; Oliva J; Kosutic G
    J Clin Pharmacol; 2008 Feb; 48(2):193-202. PubMed ID: 18199894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study.
    Wiemer M; Seth A; Chandra P; Neuzner J; Richardt G; Piek JJ; Desaga M; Macaya C; Bol CJ; Miquel-Hebert K; De Roeck K; Serruys PW
    Am Heart J; 2008 Oct; 156(4):751.e1-7. PubMed ID: 18926156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood concentrations of everolimus are markedly increased by ketoconazole.
    Kovarik JM; Beyer D; Bizot MN; Jiang Q; Shenouda M; Schmouder RL
    J Clin Pharmacol; 2005 May; 45(5):514-8. PubMed ID: 15831774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
    Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Merschman SA; Strohmaier KM; Ramael S; Lasseter KC; Stone JA; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2008 Feb; 83(2):293-9. PubMed ID: 17713476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
    Faessel HM; Gibbs MA; Clark DJ; Rohrbacher K; Stolar M; Burstein AH
    J Clin Pharmacol; 2006 Dec; 46(12):1439-48. PubMed ID: 17101743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.
    Yan JH; Bifano M; Olsen S; Smith RA; Zhang D; Grasela DM; LaCreta F
    J Clin Pharmacol; 2006 Nov; 46(11):1250-8. PubMed ID: 17050790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients.
    Budde K; Fritsche L; Waiser J; Glander P; Slowinski T; Neumayer HH;
    Eur J Med Res; 2005 Apr; 10(4):169-74. PubMed ID: 15946913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.